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Precision medicine (PM) can be defined as a predictive, preventive, personalized, and participatory healthcare service
delivery model. Recent developments in molecular biology and information technology make PM a reality
today through the use of massive amounts of genetic, ‘omics’, clinical, environmental, and lifestyle data. With
cancer being one of the most prominent public health threats in developed countries, both the research community
and governments have been investing significant time, money, and efforts in precision cancer medicine (PCM).
Although PCM research is extremely promising, a number of hurdles still remain on the road to an optimal integration
of standardized and evidence-based use of PCM in healthcare systems. Indeed, PCM raises a number of technical,
organizational, ethical, legal, social, and economic challenges that have to be taken into account in the development
of an appropriate health policy framework. Here, we highlight some of the more salient issues regarding the standards
needed for integration of PCM into healthcare systems, and we identify fields where more research is needed before
policy can be implemented. Key challenges include, but are not limited to, the creation of new standards for
the collection, analysis, and sharing of samples and data from cancer patients, and the creation of new clinical
trial designs with renewed endpoints. We believe that these issues need to be addressed as a matter of priority by
public health policymakers in the coming years for a better integration of PCM into healthcare.
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Precision medicine (PM) is an evolution of contempor-
ary medical practice towards more-efficient prevention
and treatment strategies. It can be defined as a predict-
ive, preventive, personalized, and participatory health-
care service delivery model. PM is generally viewed with
enthusiasm and optimism by the scientific community
[1, 2] and in the media [3, 4]. As cancer is one of the
most prominent causes of death and morbidity in devel-
oped countries [5], governments have invested massively
to make it the ‘poster child’ of PM. Genomic research
results are providing us with a more thorough under-
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actionable, and highly publicized examples demonstrate
significant improvements in prevention, survival, and
quality of life of patients with certain cancers. Neverthe-
less, the responsible clinical translation and uptake of
precision cancer medicine (PCM) into healthcare sys-
tems remains contingent on the proven scientific validity
and clinical utility of new genomic sequencing technolo-
gies, and on the development of an appropriate policy
framework. We define the PCM policy framework as a
collection of regulations, laws, guidelines, and policies
applying to PCM. This framework will be different in
each specific context, whether local, regional, national, or
international. Indeed, PCM raises a number of technical,
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of PCM into the healthcare system.
Here, we discuss key challenges and opportunities re-
garding the development of a healthcare policy frame-
work for PCM. After describing the current contribution
of genomics to PCM, in prevention, classification, and
treatment, we highlight a few areas where there is a clear
need for new standards. These include genomic data
production, analysis, and sharing, as well as clinical trial
design and cost assessment of personalized therapies.
Finally, we identify a number of fields where more research
is needed before policy can be implemented.
The contribution of genomics to PCM practice
In this section, we highlight how recent genomic re-
search results have already started to impact the practice
of medicine, both in cancer prevention and treatment, as
summarized in Table 1. Nevertheless, a number of
challenges remain, which are also summarized.
Cancer prevention
Genetic testing has already been integrated into routine
cancer primary prevention (for example, risk reduction)
as well as secondary prevention (for example, screening
and early detection) strategies. One clear example is
screening in the BRCA1/BRCA2 genes followed by
adapted preventive measures (intensified mammography
or removal surgery), which have been shown to signifi-
cantly reduce breast cancer-associated risks among
BRCA1/2 mutation carriers [6, 7]. More and more risk-
prediction models, such as BOADICEA (Breast and
Ovarian Analysis of Disease Incidence and Carrier Esti-
mation Algorithm), BRCAPRO, and IBIS (International
Breast Cancer Intervention Study), consider genetic sta-
tus (in BRCA1/2 and in other common germline vari-
ants associated with a small increase in risk [8, 9]) along
with other information, including age, ethnicity, family
history, lifestyle, and environmental factors, to assess the
risk of an individual developing breast cancer [10]. Pub-
lic health measures have been taken to create stratified
prevention and screening programs based on these more
precise individual risk calculations [11]. The use of next-
generation sequencing (NGS) technologies, which areTable 1 The contribution of genomic information to precision canc
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Early detection Liquid bio
Accurate diagnosis Using mo
Targeted therapy EGFR inhi
carriers; Tmore rapid and high-throughput than traditional Sanger
sequencing, could allow for the genetic testing of muta-
tions in all cancer-susceptibility genes for a large popula-
tion of individuals, regardless of their family history of
cancer [12]. Thanks to the drastic fall in costs of NGS
technologies [13], population-based genetic testing using
NGS might soon allow for a more systematic identification
of cancer-susceptibility mutation carriers at an acceptable
cost for the healthcare system.
Another promising avenue to reduce cancer burden is
to enable the detection of cancer cells at the earliest pos-
sible time. Recently, sizable research efforts have been
dedicated to the field of ‘liquid biopsies’—the detection
of small amounts of circulating tumor DNA in the blood
of patients—before tumors are visible though imaging
[14–16]. Although the accuracy of detecting cancer-
related events in liquid biopsies requires further im-
provement, the concept of cancer early detection and
treatment outcome prediction from a simple blood test
has prompted significant hope for many cancer patients
and interest from the private sector; Illumina has re-
cently launched a spinoff company, GRAIL [17], that
aims to market a simple blood test for early detection of
cancer in asymptomatic patients.
Tumor classification
The increased use of NGS in research has enabled
the development of new strategies to classify tumors
according to their mutation status or other biochem-
ical features, rather than their histology or tissue of
origin. For instance, a recent study showed that the
sequencing of a panel of genes related to brain tu-
mors can be used in routine neuropathology diagnos-
tics and enables the identification of glioma molecular
subgroups [18]. Another study identified potential
drug targets in 85 % of the samples the authors ana-
lyzed (169 of 200) by using gene panel sequencing on
samples where the site of the primary tumor was un-
known [19]. Some of these molecular findings are be-
ing included in new guidelines, such as the recent
World Health Organization classification of tumors of
the central nervous system [20], which includes a
number of molecular markers.er medicine
ample(s)
esting of BRCA1/BRCA2 in hereditary breast cancer and ovarian cancer;
H6/MLH in hereditary nonpolyposis colorectal cancer; RB1 in retinoblastoma
psies
lecular markers in tumor classification
bitors to treat EGFR mutation carriers; BRAF inhibitors to treat BRAF V600E
yrosine-kinase inhibitor to treat BCR–ABL fusion protein
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The use of treatment options that specifically target gen-
omic alterations found in tumors has fundamentally
changed the field of cancer therapeutics. Indeed, these
‘targeted therapies’ act on specific mutations identified
as ‘drivers’ of cancer progression (for example, erlotinib
and gefitinib inhibiting tumors with EGFR mutations in
lung cancer; vemurafenib and dabrafenib inhibiting
BRAF mutations in melanoma; imatinib and dasatinib
targeting BCR-ABL translocations in chronic myeloid
leukemia; or olaparib inhibiting BRCA1/BRCA2/PALB2
in ovarian cancer). These have already clearly benefited
patients, with improved treatment efficiency and re-
duced toxicity in non-tumor cells [21] as compared with
traditional chemotherapy and radiotherapy. Another re-
search field that is generating significant hope to im-
prove our capacity to treat cancer is that of immune
therapy. Indeed, many newly developed targeted therap-
ies based on immune checkpoint-inhibiting processes
can induce immune response and rapid tumor regres-
sion as a result of a decrease in immunosuppression
[22–24]. Combining targeted therapy with immunother-
apy is an extremely promising strategy to improve
clinical outcomes for cancer patients [25–28].
Challenges ahead
Still, to date, there are fewer than 30 approved pharmaco-
genomic drugs for cancer [29], which benefit a relatively
low number of patients. Their efficiency has been limited,
notably owing to intra-tumor heterogeneity [30, 31]
and the development of resistance mechanisms which
remain poorly understood [30, 32]. Even though the
technologies are becoming more accurate and cheaper
by the month, the turnaround time from obtaining gen-
omic material, to accurate diagnosis, and to effective
drug prescription still needs to be shortened. A recent
project using whole-genome sequencing (WGS) showed
that the median time from collecting a patient biopsy
to delivering the personalized cancer treatment report
was 58 days, still considerably above the 10- to 14-day
delay that most patients and physicians would find
acceptable [33].
In addition, the impressive advancements [34] and frus-
trating hurdles associated with the use of genomics in the
field of oncology should not allow us forget that, to truly
deliver individualized cancer solutions, we will also need
to achieve a better understanding of the contribution of
patients’ environmental, lifestyle, and psychological factors
to cancer development and progression.
Existing standards challenged, new standards
needed
To date, genomic information is collected from a minor-
ity of cancer patients, usually in the context of clinicalresearch rather than standard-of-care procedures. How-
ever, the situation is evolving rapidly, and the penetra-
tion of NGS technologies in the clinical realm has
prompted the development of new laboratory guidelines
and standards for NGS data production, analysis, and
sharing. These efforts have been made by a variety of
groups and institutions around the world, which resulted
in the publication of numerous partially overlapping
guidelines, some extremely general [35] and others focus-
ing on specific diseases, or specific steps in the process,
such as the return of results to patients and clinicians
[36, 37], or the development of specific bioinformatics
pipelines for NGS data analysis [38].
In 2014, Bennett and Farah [31] had already identified
more than 15 guidelines applicable to the field of oncol-
ogy, and more have been published since, such as the
European guidelines for clinical NGS [39]. More recently,
Nicol and colleagues [40] have eloquently referred to the
precision medicine regulatory landscape as a ‘soup’. In
addition to the publication of new guidelines, important
implementation initiatives have been undertaken in the
field of genomics. Two such notable initiatives taking
place in the USA are the National Human Genome
Research Institute's Implementing Genomics in Practice
(IGNITE) project [41], and the National Academies of
Sciences, Engineering and Medicine's roundtable on
translating genomic-based research for health, which
recently published a workshop summary on applying an
implementation science approach to genomic medicine
[42]. This is of key importance to ensure that guidelines,
once published, are actually followed by clinicians and the
PCM medical community at large [43–45]. Aside from
the clear need for more international and inter-sectorial
collaboration in this field to avoid policy redundancy and
misalignment, and to ensure efficient implementation,
here we highlight significant issues that are specific to
PCM. These issues relate to the production, analysis,
interpretation, and sharing of cancer patient samples
and data, as well as to the need for new clinical trial
designs, renewed clinical endpoints, and ethical, legal,
and social norms.
Next-generation sequencing clinical data production
Tumor samples extracted from patients can suffer from
low quantity, quality, and purity of tumor cells.
Formalin-fixed paraffin-embedded (FFPE) samples are
the current gold standard, and most commonly used in
clinical laboratories because they can be easily archived
and offer a good accuracy for cell morphology-based
diagnostics. However, FFPE-derived DNA is usually
highly degraded and contaminated by proteins. This low
DNA and RNA quality and high DNA fragmentation
rate yields a high sequencing error rate. Fresh-frozen
samples, by contrast, generally ensure access to the best
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certain advantages over FFPE samples in detecting
cancer-driving events. However, fresh-frozen samples are
currently not widely used in routine clinical molecular
analysis, and are not always available for all cancer
patients. Tumor DNA can also be extracted from diag-
nostic biopsies, but this approach is limited because the
size of biopsies performed for diagnosis purposes is
usually kept to a minimum [46].
Considering the usefulness of obtaining tumor gen-
omic information for cancer diagnosis, prognosis, and
treatment, important steps have to be taken to enable
the development of renewed standards for state-of-the-art
molecular-pathology procedures. This can be achieved by
reforming practices of surgeries and pathology laborator-
ies in order to ensure that tissue extraction, preparation,
and storage methods are geared towards maximum
preservation of DNA (or other molecular features, such
as RNA and the methylome) rather than cell morph-
ology, while ensuring maximum safety for patients.
However, changing practices and standards in a spe-
cialty service takes time, and relies on the commitment
of all stakeholders involved in the sample preparation
process, from surgeons to pathologists to laboratory
technicians. In addition, although guidelines can be
issued by professional societies or other government
institutions, their implementation has to be adapted for
each local laboratory.
After sample collection, steps should be taken at the
level of DNA extraction, library preparation, and sequen-
cing experiment design to extract enough high-quality
material to perform molecular testing. Significant research
efforts have been dedicated to determining how to coun-
teract the effect of low DNA quantity by using a higher
sequencing depth. Just how much coverage is enough to
ensure maximum sensitivity and specificity of mutation
detection is still a matter of debate, and clinical standards
should be developed.
Next-generation sequencing data analysis
Once the sequencing data are collected, and before data
interpretation can take place, additional steps have to be
taken to estimate tumor purity and to evaluate the
amount of contamination by non-tumoral DNA. Bio-
informatics pipelines should be adjusted to counter this
effect and accurately call somatic variants present in the
tumor. Once again, research efforts have been made to
establish a computational platform for clinical analysis
of sequencing data from FFPE samples [47]. However,
formal clinical standards are still needed.
As mentioned above, another hurdle that has to be
overcome is tumor heterogeneity. Mutations that are
present in subclones within the tumor population, in a
low allelic fraction, are difficult to identify [48]. However,their substantial role in generating resistance mecha-
nisms makes them a key element in treatment decisions.
Indeed, precision therapies that target and eliminate the
major clone also change the tumor environment and
provide space for the expansion of minor clones. The
accuracy of detecting subclonal mutations partly relies
on the computational pipeline used, and several studies
have focused on comparing the performances of different
variant-calling algorithms [49–51]. However, no rigorous
computational tool has been validated for clinical genetic
testing in cancer.
There is a clear need to test the performance of bio-
informatics software and pipelines for the clinical ana-
lysis and clinical interpretation of NGS data and to have
them approved by regulatory bodies such as the US
Food and Drug Administration (FDA), its sister agency
the Centers for Disease Control and Prevention (CDC),
or the European Medicines Agency (EMA) [52]. Consid-
ering that current practices are highly divergent, as
highlighted by the Children’s Leadership Award for the
Reliable Interpretation and Appropriate Transmission of
Your Genomic Information (CLARITY) challenge [53]
and, more recently, by the Clinical Sequencing Explora-
tory Research (CSER) consortium [54], these institutions
have launched initiatives to develop or compare the
performance of statistical models and bioinformatics
tools fit for NGS data analysis, and the CDC recently
published their recommendations [38]. However, those
recommendations are focused on detecting germline
mutations, which are an order of magnitude less com-
plex and heterogeneous than somatic cancer mutations.
Data interpretation and sharing
To make clinical sense of the cancer genome of an indi-
vidual patient, in addition to using specialized bioinfor-
matics tools to predict the functional effect of specific
alterations, one has to compare it with thousands of
other non-cancer and cancer genomes. A series of filter-
ing steps have to be performed to identify the one or
few mutations that are of interest among the thousands
of alterations found in a patient’s tumor, each relying on
accessing comprehensive and curated databases. In the
description below, we are taking the example of the at-
tribution of a targeted treatment, but the same principles
are used when looking for a prognosis, treatment side-
effect, or resistance biomarker.
When possible, mutations that are common in the
general population, and therefore unlikely to have
caused the cancer, should be excluded. To perform this
step, one has to access large databases of population al-
lele frequencies, such as the 1,000 genomes project [55],
dbSNP [56], the Exome Aggregation Consortium (ExAC)
[57], and the Exome Variant Server [58]. Although these
exist, they are incomplete, biased towards genomes of
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thermore, among the multiple potentially causal somatic
mutations found in a tumor, one has to identify those
that are driving oncogenesis, as opposed to ‘passenger
mutations’ which have no effect on cancer development.
This is usually attempted by searching for mutations
already found to drive tumors in other cancer patients.
These searches are performed in large-scale publically
accessible databases such as the Catalogue of Somatic
Mutations in Cancer (COSMIC) [62], the cBioPortal for
Cancer Genomics [63], the Therapeutically Applicable
Research to Generate Effective Treatments (TARGET)
[64], the Pediatric Cancer Genome Project [65], or the
‘My Cancer Genome’ tool [66]. In addition, most clinical
research laboratories use their own patient genome data-
bases. Those can be difficult to share with the wider
community if they contain specific patient information
or if they were obtained in a strict clinical setting with
no consent to share the data for research. This
phenomenon has been particularly reported in the field
of rare diseases [67], and the recent European Society of
Human Genetics guideline specifically encourages clin-
ical laboratories to share these locally accumulated data
[39]. Researchers can also apply for access to raw se-
quencing data created by two large-scale international
cancer sequencing initiatives, namely The Cancer Gen-
ome Atlas (TCGA) [68] and the International Cancer
Genome Consortium (ICGC) [69]. Nevertheless, those
databases would be more valuable if they would system-
atically gather clinical and demographic data. The next
evolution of the ICGC project, ICGCmed, promises to
collect a much richer dataset to enable personalized
medicine [70]. Similarly, the Sharing Clinical Reports
Project (SCRP) has been initiated by ClinVar and aims
to collect the identification and clinical interpretation of
BRCA1/2 variants. The Global Alliance for Genomics
and Health (GA4GH) [71] also launched the BRCA chal-
lenge demonstration project [72], providing an efficient
platform with all BRCA mutations collected from pa-
tients around the world, together with their phenotypic
characteristics. Following this push from the research
community for a more systematic sharing of all patient
cancer genome data, the for-profit diagnostic company
Ambry Genetics recently announced the publication of
more than 10,000 whole exomes from cancer-diagnosed
clients in the open access database AmbryShare [73, 74].
To increase the pool of cancer exome data, and to push
for a faster implementation of PCM, the company Strata
Oncology has raised capital to offer free DNA sequen-
cing to 100,000 US cancer patients [75].
Once likely driver mutation(s) have been identified in
the patient tumor genome, the next step is to find those
that are ‘actionable’, or targetable by a therapeutic agent.
If such an agent exists, and is manufactured, the decisionon whether and how to use it to treat the cancer patient
depends on a number of factors. In the best-case scenario,
the agent exists and has been approved by the local regu-
lation agency for patients with the same characteristic
(such as cancer type and stage, age, previous treatment
course). Accessing approved drug databases is relatively
straightforward, notably with the use of pharmGKB [76],
an online resource that provides a list of most, if not all,
pharmacogenomics agents approved or under consider-
ation by the FDA, EMA, and others, and containing a
wealth of information on each agent. In a more likely
scenario, the agent might have been approved to treat
patients with a different cancer or age group (as often
happens for pediatric patients, as significantly more trials
are launched with adults as compared with children). In
this case, the treating oncologist has to decide whether to
provide the drug ‘off label’ to the patient or to add the
patient to an existing clinical trial where he/she could also
receive the drug and be monitored (providing funding is
available). Oncologists make these decisions based on a
set of criteria that can include existing formal or informal
hospital policies, their knowledge of the clinical features
of the patient, and the practice of their colleagues in the
field. Once again, accessing the information about existing
clinical trials requires the use of up-to-date and reliable
databases. The US National Institutes of Health (NIH)
maintains a relatively complete database freely accessible
online [77], which includes trials registered in the USA
and around the world. Most clinicians rely on their profes-
sional networks to have access to information on existing
trials, whether it is directly with agent manufacturers,
pharmaceutical companies, or other clinicians. Another
issue is that of accessing results of clinical trials, and shar-
ing information on the positive or adverse reactions of
patients to treatment regimens. There again, efficient and
systematized reporting strategies have to be put in place
so that clinicians and patients can take informed decisions
on the course of care [78].
Finally, data sharing is necessary to enable a more sus-
tainable and reliable discovery and exploitation of bio-
logical links between compounds and diseases [52]. The
pharmaceutical industry is getting increasingly involved
in this research. AstraZeneca, for example, announced
early in 2016 that it would analyze the genomes of two
million patients to help inform its drug discovery research
and share the insights generated by the sequencing,
including information on variant data and drug targets,
with the research community [79].
Test selection
Although most cancer patients who undergo genetic
analysis today have access to targeted tests, current NGS
strategies include sequencing of a panel of known cancer
genes, or the entire protein coding region of the genome
Bertier et al. Genome Medicine  (2016) 8:108 Page 6 of 12(whole-exome sequencing, WES), WGS or sequencing
the entire transcriptome (RNA-seq). Ordering the right
test for a particular cancer patient requires a compre-
hensive evaluation of their clinical features, at an accept-
able turnaround time and affordable cost [80]. Gene
panel sequencing is the cheapest and perhaps the most
effective method to identify an ‘actionable’ mutation be-
cause, to date, only a limited number of cancer genes
can be matched to a targeted therapy. The WES and
WGS strategies are the most ‘hypothesis-free’ approaches,
and they are more likely to uncover novel mutations that
can be matched to a new drug that has not been used in
cancer before. However, WES and WGS are more costly
in data production, storage, and in computation. In
addition, owing to the biased coverage of these techniques
towards low-complexity regions in the genome, validation
assays have to be performed for each of the candidate
variants uncovered through WES or WGS. This entails
non-negligible additional time and costs [81, 82]. WGS
has several advantages over WES, including the identifica-
tion of regulatory variants that affect gene expression, and
structural variants in which the breakpoints are located
outside exons. RNA-seq is complementary to DNA se-
quencing as it directly measures gene expression, splicing
variants, and gene fusions. In the future, the tumor and
matched normal whole-genome of each patient could be
sequenced at diagnosis and be made available in their
medical records before clinicians make treatment deci-
sions. However, before that time comes, new guidelines
are needed to help clinicians decide which is the most
appropriate test to prescribe to their patients.
Cost of drugs and clinical trials design
Calculating the absolute cost-effectiveness of persona-
lised interventions is far from easy. In a systematic re-
view published in 2014, the authors failed to determine
whether ‘individualized medicine interventions’ were
more or less cost effective than standard-of-care inter-
ventions—their admittedly disappointing answer to this
question was “it depends” [83].
PCM could be less cost efficient for a number of rea-
sons: because the cost of developing and marketing a
biological drug is extremely expensive, this investment is
justified only if the target population for the drug is
large, and if the benefits and gains in ‘quality-adjusted
life years’ (QALY) are sizable. By definition, targeted
therapies have a small beneficiary population size, and
are therefore less cost-effective. One should also con-
sider the potential need for many more clinical trials
than for untargeted chemotherapies [84]. In addition,
personalized therapies are some of the most expensive
drugs currently on the market [85, 86]. However, a num-
ber of elements complicate this simplistic picture, lead-
ing many to argue that traditional cost-effectivenesscalculations have to be re-thought in the context of
PCM [87]. First, improved ‘personalised’ risk prediction
models could allow substantial healthcare savings by im-
proving chances for early detection and management of
cancer [12]. Second, although niche oncology drugs are
expensive, the costs of biomarker detection are dimin-
ishing (currently between $100 and $5000 per patient)
[87, 88], notably owing to the progress made in the fields
of bioengineering and the increased use of nanotech-
nologies [89]. Third, contrary to personalized drug
development, the use of genomic tests to adjust the
dosage of an already approved medication or to substi-
tute an approved drug for another seem to be intui-
tively very cost efficient. Doing so allows for a more
rational and safe drug use (i.e., less hospitalization from
adverse effects) at little extra cost [90]. Indeed, many
cancer patients harbor mutation patterns that are
already targeted by approved agents, either in other
cancers or other diseases. This significantly expands the
possibilities for drug repositioning, removing the cost
of phase I and phase II experiments, and moving dir-
ectly to phase III trials or even N-of-1 trials [78]. These
smaller, more targeted clinical trials with more strictly
selected patients, and with a higher chance of success,
could be highly cost effective [90, 91]. Fourth, the po-
tential market size of PCM drugs might not be that
small. Indeed, research results show that a limited
number of pathways are implicated in tumorigenesis,
and regulate mechanisms comprising the “hallmarks of
cancer” [92]. Patients with pathophysiologically differ-
ent cancers sometimes share the same mutation pat-
terns, and could therefore be included in the same
trials. New types of dynamic multi-armed trials based
on the patients’ molecular patterns are already under
way [93–97]. Admittedly, their actual cost efficiency
and success rate remain to be determined. Neverthe-
less, all these factors combined have led some authors
to predict that the market might be flooded by a ‘tsunami’
of targeted therapies in the near future [98].
Finally, it has been suggested that a renewed, more
comprehensive approach has to be taken when defining
intervention endpoints. Gold standards such as QALYs,
progression-free survival, and clinical utility have to be
complemented by other ‘real-world’ measures taking
into account actual patient and clinician experiences
with the treatment, as well as more general societal pref-
erences and values [99]. In addition, careful evaluation
of psychosocial as well as economic costs of adverse ef-
fects to therapies have to be included in cost-efficiency
calculations [90]. These renewed endpoints, combined
with dynamic reimbursement models, such as reim-
bursement with evidence collection [42], could promote
an efficient and timely integration of PCM into the
public healthcare system.
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Without necessarily creating a complete new set of legal
and ethical issues, the advent of PM has made the
border between research and healthcare increasingly
porous [100–102]. This uncertainty challenges policy-
makers to find new policy tools and solutions to protect
traditional principles and norms such as informed con-
sent, return of results, privacy and confidentiality, and
benefit sharing [103–105]. Given that research is an
increasingly international endeavor, whereas healthcare
is still defined at the national or regional level, these
questions will need to be answered at different geo-
graphical layers, while promoting normative coherence
and integration. Professional organizations, industry, and
non-governmental organisations—such as the Public
Population Project in Genomics and Society (P3G) [106]
and GA4GH—are all contributing to this normative
process, and they would be well advised to collaborate
closely to facilitate policy interoperability and avoid the
concurrent development of misaligned norms.
Research needed before implementation
Identification of unresolved scientific questions
As argued by Blay and colleagues in a recent review
[84], the field of PCM would benefit from the system-
atic, periodic, and, if possible, consensual establishment
of research priorities by the scientific community. This
would be extremely helpful for policymakers to target
promising fields of research and invest in the necessary
improvements of care. In addition, it would contribute
to the design of governance structures that anticipate
future societal needs, and guide the development of
technologies such as genomics towards resolving current
and future issues [107]. Such publications could stem
from high-level international meetings such as the re-
cent International Congress on Personalised Healthcare,
which took place in Montreal in June 2016 [108].
Non-genetic aspects of cancer
In making decisions on how to implement PCM, policy-
makers also have to take into account elements that
greatly influence cancer incidence and prevalence in the
population, but which are not genetic. Several types of
environmental and behavioral risk factors also have to
be considered: first, those that have been unequivocally
associated with an increased cancer risk, such as smok-
ing, radiation, sun exposure, and certain infections (for
example, the human papillomavirus causing cervical
cancer); and second, those that might have a protective
effect on cancer such as a healthy diet and regular phys-
ical activities. For those two types of factors, clear policy
guidance and prevention campaigns targeting the gen-
eral population can be designed. By contrast, ensuring
public buy-in to prevention through changes in lifestyleremain very challenging for public health policymakers
[109–113]. Finally, certain factors have been shown to
have an equivocal effect on cancer risk, progression, and
survival (for example, the use of oral contraceptives,
which has both protective and risk increasing effects on
breast and ovarian cancer [114, 115]). There are also
important social determinants of cancer incidence and
mortality [116, 117], which have a tendency to be over-
shadowed by the appeal of new technologies in genetics
and the media portrayal of the promises of PM. Clearly,
more research and high-quality evidence are needed to
better understand the joint impact of genetic and non-
genetic factors on cancer risk and survival [118]. Ad-
vancement in technology that generates ‘hype’ [119]
should not overtake research funding, and policy efforts
to reduce inequalities and incidence of deprivation-
associated cancers, such as lung and head and neck
cancer [120], should be maintained.
General questions on precision medicine
In addition to the issues described, which can be specific
to cancer, a number of issues pertain more generally to
the implementation of PM.
Patients’ preferences: new evidence needed
Published evidence on the acceptance of genomic sequen-
cing by patients is compelling. Patients are overwhelmingly
positive towards these new techniques [90, 121–123].
Nevertheless, more comprehensive research is needed to
understand patient preferences in a variety of cancer con-
texts. From existing evidence, it is clear that, if PM inter-
vention is offered in the context of a clinical research
project, as a ‘last chance’ for patients who do not respond
to standard-of-care treatments, they are highly likely to
agree to participate in risky trials and to test new therapies.
Could the same conclusion be drawn in cases where
chemotherapy is associated with a better or a similar
prognosis compared with that of a PCM intervention?
In addition to patients, it is important to consider the
opinions of healthcare professionals and the general
public on PCM [84]. Real-world data are greatly needed
to understand patients’ experiences with different toxic-
ities, their individual tolerance to risk and risk–benefit
balance, and what they consider a most desirable outcome
from a treatment [90].
Access to precision medicine
Today, access to PM is restricted to certain large-scale
cancer centers in developed countries, and is not avail-
able in smaller centers in most of the developing world.
Access can also be dependent on regional infrastructure,
market size, and the political capacity to negotiate special
agreements with pharmaceutical companies for access to
new treatments. At the national level, access to certain
Table 2 Integrating precision cancer medicine into healthcare—key challenges and opportunities
Area Challenge Opportunity
Medical Practice
Detection Many cancers diagnosed too late Liquid biopsies
Turnaround time Time from sample collection to clinically actionable
result often too long
Optimization of sample collection and data
analysis pipelines
Treatment Limited efficiency of targeted treatments Research on resistance mechanisms and tumor





Multiple partly overlapping guidelines published,
poor international and inter-sectorial operability
Collaborations between agencies such as the
FDA, the EMA, Health Canada, and the NHS.
Implementation projects (IGNITE and others)
Sample collection Current gold standard (FFPE) suboptimal for genomic
data analysis.
Standardization and implementation of new
cancer sample collection strategies (for example,
fresh frozen) to maximize quality, quantity, and
purity of tumor cells.
Sample preparation and analysis Suboptimal DNA extraction, library preparation, and
sequencing protocols for molecular testing of cancer
samples
Implementation of new standards to counteract
unavoidable cancer sample limitations (low quality,
quantity and purity, high heterogeneity)
Cancer genomic data analysis Current bioinformatics pipelines and software
suboptimal for the identification of actionable
cancer mutations
Development and clinical validation of bioinformatics
tools and pipelines for a thorough molecular analysis
of tumor samples (including main and subclonal
mutations, and cellular context)
Cancer genomic data sharing Genetic diversity of the general population and
cancer patients poorly represented in current
publically available databases.
Development of improved and curated cancer-specific
and population databases
Widely variable data sharing policies among clinical
institutions and research projects
Alignment of international policies on cancer patients’
data sharing
Clinical trials and compound registration fragmented
and patchy
Improve databases of approved compounds and
international clinical trial registries
Test selection Widely variable genetic testing practices for similar
cancer patients across clinical institutions
Production of clinical guidelines on genetic test
selection (single gene/gene panel/whole exome/
whole-genome sequencing)
Clinical trials and cost of drugs Classical clinical trial designs (large and diverse
patient populations) inappropriate to test targeted
therapies
New clinical trial designs: drug repositioning tests,
‘n-of-one’ trials, rotation therapies
Cost-effectiveness of targeted therapies widely
contested
Thorough examination of cost-effectiveness of
cancer genomic medicines, taking into account
new clinical trial designs
Intervention endpoints Traditional endpoints and measures (QALYs)
ill-adapted to personalized medicine interventions
Renewed, more holistic intervention endpoints,
including patient experience, societal preferences,
and values
Policy, ethical and legal norms Border between research and healthcare
increasingly porous
Development of adapted, international and
interoperable ethical and legal norms
(GA4GH, P3G)
Higher uncertainty associated with the clinical
significance of genomic information
Tension between international research endeavors
and national healthcare systems
Pre-implementation research needed
Identify priorities Need for a systematic identification of unresolved
scientific questions
International conferences and expert reviews in PCM
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Table 2 Integrating precision cancer medicine into healthcare—key challenges and opportunities (Continued)
Non-genetic aspects of cancer A number of elements still poorly understood
• Environmental factors
• Behavioral factors
• Social determinants of cancer incidence and survival
Support for targeted research in those domains,
while continuing efforts to reduce known factors
leading to increased cancer incidence and prevalence
(smoking, alcohol consumption, and social deprivation)
EMA European Medicines Agency, FDA Food and Drug Administration, FFPE formalin-fixed paraffin-embedded, GA4GH The Global Alliance for Genomics and
Health, IGNITE Implementing Genomics in Practice, NHS National Health Service, PCM precision cancer medicine, P3G Public Population Project in Genomics and
Society, QALY quality-adjusted life years
Bertier et al. Genome Medicine  (2016) 8:108 Page 9 of 12off-label or clinical trial treatments can still be dependent
on the hospital where the patient receives care, and on the
presence of clinical researchers among the oncology team.
Straightforward solutions still have to be put forward to
ensure an equitable access to PCM, both in clinical re-
search and when it becomes standard of care, nationally
and internationally.
Infrastructures and education
Undoubtedly, significant investments have to be made in
two areas to enable PM. First, infrastructures have to be
put in place to produce, store, link, and share the data.
This includes sequencing technology equipment, secure
high-throughput computing infrastructures, as well as
reliable and standardized electronic health record sys-
tems integrating genomic and phenotypic patient infor-
mation. Second, the general public, clinicians, and other
stakeholders such as insurance providers all have to be
educated about PM. Informing the general public will
increase the level of participation in crucial initiatives
such as large-scale population sequencing, as well as
disease-specific research. Clinicians at all levels also need
to be educated and engaged in PM initiatives, and a
greater number of genetic counsellors integrated within
healthcare teams. This is crucial to ensure an efficient
uptake of available techniques and treatment options, so
that PM research efforts are actually translated to daily
patient care [104, 124]. These education efforts have to
be made on top of the publication of official clinical
practice guidelines [90, 125].
PM implementation: a local question?
Solutions need to be designed to reconcile the inter-
national collection of scientific evidence of clinical valid-
ity and clinical utility of PM interventions, and the
necessary local calculations of cost-effectiveness and
reimbursement procedures. Indeed, these last consider-
ations are highly dependent on the healthcare system
organisation, guiding principles, political, cultural, and
economic context. Individual nations alone will be able
to make implementation choices that they deem appro-
priate in their local context. Nevertheless, a number of
large-scale international initiatives have taken place that
aim to share implementation results and benefits from
PM. These are listed and described in a recent review by
Manolio and colleagues [126]. Despite this, as concludedby the authors, more globalized efforts are needed to
make sure as little unnecessary duplication of efforts as
possible is performed.
Conclusions
We have attempted to highlight some of the salient is-
sues in the implementation of PCM. As summarized in
Table 2, we have described a number of areas in which
new standards need to be established before PCM imple-
mentation, including the collection, analysis, and sharing
of cancer patient samples and data, as well as the need
for new clinical trial designs. In addition, we have identi-
fied areas where significant research efforts are needed
before PCM policies can be established, notably regard-
ing the non-genetic aspects of cancer. This discussion is,
by choice, more selective than comprehensive, and some
elements might be missing from this list. However, we
have identified broad themes that we think should be
tackled by policymakers who are presently taking deci-
sions on PCM implementation. A better understanding
of the complex scientific and policy issues posed by
PCM by all stakeholders is desirable in order to find so-
lutions and improve the translation of PM in public and
private health systems.
Potential future avenues include promoting invest-
ments in infrastructures and promising research fields,
an increased effort in education and training of health-
care professionals about PCM, and the design of more
suitable models to evaluate the cost-effectiveness of
personalized interventions. We are extremely positive
on the potential of PM to improve cancer care in the
future; however, in the current transition period, it is of
prime importance that the public be accurately informed
and engaged on this topic. Most cancer diagnostics today
still come with a grim prognostic, and it would be unfor-
tunate to see patients develop inappropriate expectations
of ‘miracle’ PCM cures. We therefore call for the promo-
tion of a balanced portrayal of what PCM is, its limits, and
what it can do for cancer patients today, both in the
research literature [127–129] and in the media.
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